HOUSE_OVERSIGHT_028418.jpg
3.34 MB
Extraction Summary
2
People
8
Organizations
1
Locations
4
Events
3
Relationships
5
Quotes
Document Information
Type:
Web article / digital document, likely an exhibit from a u.s. house oversight investigation, bearing the label 'house oversight 028418'.
File Size:
3.34 MB
Summary
This document is a digital article, labeled for a House Oversight investigation, concerning the pharmaceutical company Celgene and its executive, Mr. Hugin. It details the company's aggressive marketing of the drug Thalomid for unapproved uses shortly after its launch, leading to multiple reprimands from the F.D.A. in the late 1990s and a whistle-blower lawsuit settled in 2017. The document is not related to Jeffrey Epstein.
People (2)
| Name | Role | Context |
|---|---|---|
| Mr. Hugin | Former Managing Director at J.P. Morgan; Top Executive at Celgene |
Joined Celgene when the company was financially struggling. He is a central figure in the article, which discusses hi...
|
| Rick Loomis | Photographer |
Credited as the photographer for The New York Times for a picture of Mr. Hugin.
|
Organizations (8)
| Name | Type | Context |
|---|---|---|
| Celgene | ||
| J.P. Morgan | ||
| F.D.A. (Food and Drug Administration) | ||
| The New York Times | ||
| Wall Street | ||
| U.S. Securities and Exchange Commission (sec.gov) | ||
| Washington Post | ||
| HOUSE_OVERSIGHT |
Timeline (4 events)
Locations (1)
| Location | Context |
|---|---|
Relationships (3)
The text states he was a 'top executive at Celgene' after leaving J.P. Morgan.
The F.D.A. reprimanded Celgene multiple times and held a meeting to warn the company about its marketing practices for Thalomid.
He is credited as a photographer 'for The New York Times'.
Key Quotes (5)
"At the time, the company’s financial situation was perilous. Celgene had 200 employees and was getting by on less than six weeks of cash when Mr. Hugin joined, according to his campaign biography."Source
HOUSE_OVERSIGHT_028418.jpg
Quote #1
"during the next several years, we will be very dependent on the commercial success of Thalomid"Source
HOUSE_OVERSIGHT_028418.jpg
Quote #2
"Drug companies are forbidden from promoting a drug for any unapproved uses, but doctors have broad discretion to prescribe a product for a range of diseases. Celgene appeared to exploit this distinction almost as soon as Thalomid arrived on the market..."Source
HOUSE_OVERSIGHT_028418.jpg
Quote #3
"The F.D.A. reprimanded Celgene multiple times in those early years... calling a meeting in December 1998 to warn of its “strong concern” that Celgene was marketing Thalomid for unapproved uses."Source
HOUSE_OVERSIGHT_028418.jpg
Quote #4
"Mr. Hugin has defended his role as a top executive at Celgene, saying that he helped lead a company that developed life-saving medicines."Source
HOUSE_OVERSIGHT_028418.jpg
Quote #5
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document